echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Since July, a number of pharmaceutical executives have left and replaced them.

    Since July, a number of pharmaceutical executives have left and replaced them.

    • Last Update: 2020-07-29
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Since July, the wave of departures in the pharmaceutical industry has continued to surgeIncluding modern pharmaceutical, chijin pharmaceutical, Yamakawa pharmaceutical, refined pharmaceutical and other pharmaceutical companies have issued an announcement of the departure or replacement of senior executives, the reasons mainly include personal reasons and job adjustmentHyundai Pharmaceuticals director resigned On the evening of July 14th, Hyundai Pharmaceuticals announced that MrYang Jun had resigned as director and president of the company for work reasonsAfter resigning, MrYang Jun will not hold any positions in the companyIt is worth mentioning that Hyundai Pharmaceuticals has issued six personnel changeannouncements in the past yearIn the first quarter of this year, the company's net profit attributable to shareholders of listed companies was 135 million yuan, down 26.86 percent from a year earlierPublic information shows that the main business of modern pharmaceutical is anti-infective drugs, cardiovascular drugs, anti-tumor drugs, hormones and regulation of endocrine system drugs, narcotic psychotropic drugsOn the same day as the departure of The Secretary of the Company, Chijin Pharmaceuticals also issued a notice of departureMrXie applied to resign as secretary of the board of directors because of the job adjustmentHowever, MrXie is still a director and vice president (deputy general manager) of the companyThe Company's first quarter 2020 report showed that the company's net profit attributable to shareholders of listed companies in the first quarter of 2020 was RMB37.7253 million, down 16.19% from a year earlierPublic information shows that The pharmaceutical industry is mainly engaged in the development, production and sale of traditional Chinese medicine, chemical drugs and feminine hygiene products, as well as the wholesale and retail business of pharmaceuticalsOn July 16, 2020, a board meeting was held to consider and approve the Bill on the Appointment of Senior Managers of the CompanyAccording to the development needs of the company, the board of directors agrees to appoint JUNLI ZHANG as the company's deputy general manager, from the date of consideration and approval of the board of directors until the expiration date, upon nomination by the general manager and the approval of the nomination committee of the board of directorsThe independent directors of the company expressed their independent opinion on the above matters and agreed to appoint JUNLI ZHANG as the Company's Deputy General ManagerFinancial data show that in 2019, the company's net profit attributable to shareholders of listed companies was -461 million yuan, compared with -440 million yuan a year earlierPublic information shows that Zeyan Pharmaceuticals is an innovative and driven chemical and biological drug research and development company focusing on cancer, bleeding and blood diseases, liver and bile diseases and other therapeutic fieldsYamhea Drug Auxiliary Non-Staff Representative Supervisor resignation July 15 news, recently Yamhea Pharmaceutical Auxiliary Supervisory Board recently received the resignation report of non-staff representative supervisor Yang Zhiyuan, Yang Zhiyuan will not be in any position in the company after his resignationFinancial data show that in 2019, the company's net profit attributable to shareholders of listed companies was RMB84.3705 million, an increase of 20.34 percent over the same period last yearPublic information shows that Yamahe pharmaceutical supplements focus on the research and development, production and marketing of pharmaceutical accessories, for the domestic ranking of oral solid preparations pharmaceutical accessories production suppliersOn July 14th, Jingjing Pharmaceuticals announced that Xie Zhangqing had resigned as a director for personal reasons, effective July 10, 2020, and would no longer hold other positions in the companyAccording to the 2019 annual report of Jingjing Pharmaceuticals, the company achieved operating income of RMB365 million in 2019, up 46.66% YoY, and net profit attributable to shareholders of listed companies was RMB307.228 million, up 104.05% YoYPublic information shows that the fine crystal pharmaceutical industry is mainly engaged in sterile api, amino acids and vitamin nutrition enhancer products research and development, production and salesOn July 8, The Assistant General Manager of Sunflower Pharmaceuticals resigned, and Sunflower Pharmaceutical SCo., Ltdannounced that MrYu had applied to resign as assistant to the general manager of the company for personal reasons and would no longer hold other positions in the companyThe first quarter of 2020 reported that the company achieved revenue of 910 million yuan, down 24.96 percent year-on-year, while net profit attributable to shareholders of listed companies was 154 million yuan, down 5.46 percent year-on-yearData show that the main business of sunflower pharmaceutical industry to produce traditional Chinese medicine as the leading, "chemical drugs, biological drugs" and "health products" as the two wings, is a drug research and development, manufacturing and marketing as one of the large-scale brand pharmaceutical group enterprises On July 8th, Shandong Unnamed Biopharmaceutical Co., Ltd issued a notice that Wang Lijun had applied to resign as secretary of the company's board of directors for personal reasons, and the above-mentioned resignation report took effect from the date of service to the board of directors of the company According to the company's 2019 annual report, the company's net profit attributable to shareholders of listed companies in 2019 was RMB63.3835 million, an increase of 161.09 percent over the same period last year Data show that the scope of unnamed pharmaceutical business for biotechnology research, biological products and corresponding high-tech products, pharmaceutical intermediates, pesticide intermediates development, production and sales
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.